16+ hour, 20+ min ago  (386+ words) The Clinical Trial Vanguard Teva Submits NDA for Ecopipam in Pediatric Tourette Syndrome Aripiprazole's FDA approval for pediatric Tourette syndrome came in December 2014, meaning a full decade has passed without a new option entering the space. Teva's NDA submission for…...

1+ day, 2+ hour ago  (473+ words) NDA submission supported by positive Phase 3 data recently published in JAMA Neurology. Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations Ecopipam could be the…...

4+ day, 22+ hour ago  (637+ words) A composition-of-matter patent (US 17/622, 451, "A series of TLR2 agonist compounds") and A method-of-use patent for the treatment of rhinovirus-mediated exacerbations of chronic obstructive pulmonary. .. ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations MELBOURNE,…...

3+ day, 6+ hour ago  (615+ words) Jun 16, 2026, 12: 28 ET MISSISSAUGA, ON, June 2, 2026 /CNW/ - GSK'announced today that Health Canada has approved Exdensur (depemokimab) for two indications: In the ANCHOR-1 and ANCHOR-2 trials, depemokimab demonstrated significant reductions in nasal polyp size and nasal obstruction versus placebo in patients with…...

3+ day, 23+ hour ago  (847+ words) Medianet News Hub ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations Melbourne, Australia, 15 June 2026 " ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory…...

3+ day, 17+ hour ago  (316+ words) CHOSUNBIZ Chosunbiz Celltrion Pharm showcases Vegzelma and Godex clinical value at Korea liver summit Celltrion Pharm said on the 16th that it took part in The Liver Week in Seoul and held academic lectures on the progressive liver cancer and metastatic…...

4+ day, 10+ hour ago  (442+ words) BIA 28-6156 didn't meet goals in Phase 2 trial involving gene mutation Written by Andrea Lobo | June 15, 2026 BIA 28-6156, a small-molecule therapy developed by Bial for GBA-related Parkinson's disease, did not slow disease progression in a Phase 2 clinical trial involving people with mutations…...

4+ day, 11+ hour ago  (75+ words) Trading View LXEO: Pivotal trial for LX2006 in Friedreich ataxia set for Q2 2026, targeting BLA in 2028 Final pivotal trial design for LX2006 in Friedreich ataxia cardiomyopathy is set, with a 6-month primary endpoint and random allocation to reduce bias. Topline data is expected…...

4+ day, 19+ hour ago  (210+ words) NEW long-term real-world data from Italy provide further evidence supporting the durability and safety of secukinumab in moderate-to-severe plaque psoriasis, according to findings from the IL PSO multicentre retrospective study. Subgroup analysis suggested that patients with concomitant psoriatic arthritis experienced…...

1+ week, 7+ min ago  (455+ words) In the Phase III LATITUDE Atlas head-to-head study (NCT06973291), Takeda's zasocitinib demonstrated statistical superiority over Sotyktu in the Psoriasis Area and Severity Index (PASI) 100 response rate at week 16, the primary endpoint. More than 35% of zasocitinib patients achieved this endpoint, more than…...